Abstract
Background The prevalence of different HPV types, especially HPV16 and 18 in cervical cancer in patients diagnosed 2019–2023 in Stockholm was compared to corresponding data from 2003–2008 before the introduction of HPV vaccination in Sweden. Material and Methods Cervical cancer samples from 125 patients diagnosed 2019–2023 in Stockholm were analysed for 27 HPV types by multiplex assay and the HPV type prevalence data was compared to data obtained in 154 cervical samples from 2003–2008. Results Patient median age was higher 2019–2023 compared to 2003–2008 (55-years vs. 42-years, p = 0.046). Overall HPV prevalence was 93.6%, HPV16 and 18 accounted for 62.2% of all squamous cell carcinoma cases (SCC) and 63.6% of all adenocarcinoma cases (ADC) vs. 92.9%, 69.7% and 88.6% respectively 2003–2008. Conclusion The joint prevalence of HPV16 and 18 in SCC and ADC tended to be slightly lower in 2019–2023 as compared to 2003–2008, but the difference was not statistically significant.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have